Endocrine Abstracts

Background: Despite adequate hormone replacement therapy, evidence suggests that mortality is increased in patients suffering from primary adrenal insufficiency (AI), mainly because of cardiovascular diseases. Since activation of the renin-angiotensin-aldosteron system (RAAS) plays an important role in the development of hypertension and cardiovascular disease we aimed to investigate, if there are differences in AI compared to healthy controls.Methods: E...

Introduction: In patients with cured Cushing’s syndrome, comorbidities often persist after remission of glucocorticoid excess. Here we investigate long-term comorbidities in patients with Cushing’s syndrome in remission, and their relationship to metabolic and hormonal markers at the initial diagnosis of the disease.Methods/design: We evaluated 118 patients with cured Cushing’s syndrome (55 Cushing’s disease, 55 adrenal Cushing’s...

Background: Despite adequate glucocorticoid (GC) and mineralocorticoid (MC) replacement therapy, primary adrenal insufficiency (AI) is associated with an increased mortality, mainly due to cardiovascular disease. The role of MC replacement is not known. Therefore we assessed whether renin concentrations during routine GC and MC substitution therapy are associated with cardiac function and morphology.Methods: 17 patients with AI underwent magnetic resonan...

Background: Craniopharyngiomas (CP) are benign brain tumours presenting in childhood treated by tumour resection together with radiotherapy. In about half of the cured patients hypothalamic damage leading to eating disorders and obesity as well as to hypopituitarism, necessitating consequent hormone substitution therapy, is observed. Bariatric surgery is an efficient treatment strategy for morbid obesity. However, so far it is unknown, whether oral hormone substitution is hamp...

PRIMARA is the first observational study to describe the demographic and clinical profiles of adults with primary hyperparathyroidism (pHPT) receiving cinacalcet in daily clinics across European countries.Patients with pHPT aged ≥18 years without prior cinacalcet treatment were eligible. Initial cinacalcet dosage and subsequent dose changes were at the investigator’s discretion. Information on dosing, biochemistry and adverse drug reactions (A...